Replies to post #11789 on Innovus Pharmaceuticals Inc. (fka INNV)

[Biotech Pharmer]

Not so sure about that, as they already have Fluticare access thru Westward. An argument could be made that the original ANDA is inconsequential. It's a bogus argument, but his guidance on "imminent approval" of Fluticare in 2016 and $10-$15M revenue guidance this year are bogus too and affect share value.